Regorafenib, a multi-kinase inhibitor, significantly suppresses tumor growth and angiogenesis in hepatocellular carcinoma (HCC), with effects similar to those of DC-101 (an anti-VEGFR2 antibody). The gene discussed is KDR; the disease is hepatocellular carcinoma.